Paid Clinical Trials in Des Moines, IA
As of August 2026, 135 paid clinical trials are recruiting in Des Moines, Iowa. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Des Moines offers studies at sites including Iowa Methodist Medical Center for conditions such as Malignant Solid Neoplasm, Anatomic Stage II Breast Cancer AJCC v8, Acute Myeloid Leukemia, Breast Cancer. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Des Moines
Trials by drug in Des Moines
Filter results
Newly added in Des Moines
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
132 clinical trials
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Top Research Study Locations in Des Moines
Researchers run research studies in Des Moines, IA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Iowa Methodist Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Chronic Lymphocytic Leukemia | 77 |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic | Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Stage III Laryngeal Cancer AJCC v8 | 74 |
| UI Health Care Mission Cancer and Blood - Laurel Clinic | Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Stage III Laryngeal Cancer AJCC v8 | 74 |
| Mercy Medical Center - Des Moines | Anatomic Stage II Breast Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8 | 67 |
| Broadlawns Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | 39 |
| Blank Children's Hospital | B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm, Acute Myeloid Leukemia | 24 |
| Iowa Lutheran Hospital | Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Digestive System Neoplasm | 7 |
| Mission Cancer and Blood - Laurel | Anatomic Stage IV Breast Cancer AJCC v8, Cardiotoxicity, Elevated CA15-3 or CEA or CA27-29 | 4 |
| Medical Oncology and Hematology Associates-Des Moines | Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma | 2 |
| MercyOne Des Moines Medical Center | Lumbar Spinal Stenosis, Mitral Valve Regurgitation | 2 |
| Mission Cancer and Blood - Des Moines | Cancer, Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 2 |
| ACCOMPLISH-2 Research Site | Chronic Weight Management, Obesity, Overweight | 1 |
| Central Iowa Hospital Corp - UnityPoint Health | COPD | 1 |
| Department of Health and Human Services | Mental Health Disorder | 1 |
| Exinia Research | Acute Gout Flare, Acute Gouty Arthritis, Gout Flare | 1 |
| Harbor View Medical | Orthopedic Disorder | 1 |
| Home-based telemedicine | Chronic Granulomatous Disease (CGD) | 1 |
| John Stoddard Cancer Center | Ovarian Cancer | 1 |
| MercyOne Iowa Heart Center | Aortic Stenosis | 1 |
| Mission Cancer & Blood - John Stoddard Cancer Center | Triple Negative Breast Cancer | 1 |
| Mission Cancer + Blood | MF, Myelofibrosis, Post-ET Myelofibrosis | 1 |
| Mission Cancer + Blood (Exigent Network) | Gastric Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer | 1 |
| Mission Cancer + Blood - IMMC | KRAS G12C Lung Cancer, Non-Small Cell Lung Cancer | 1 |
| Mission Cancer + Blood - Mission Cancer Foundation | Non-small Cell Lung Cancer | 1 |
| Mission Cancer and Blood | Breast Cancer | 1 |
Active & Upcoming Studies in Des Moines (2026)
Recruiting trials in Des Moines grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (100 active studies)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · Phase 3 · National Cancer Institute (NCI)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations · Phase 3 · SWOG Cancer Research Network
Mental health & behavior (2 active studies)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Diabetes & metabolic (1 active study)
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) · Phase 3 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Common conditions studied in Des Moines
- Malignant Solid Neoplasm (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Acute Myeloid Leukemia (4 active studies)
- Breast Cancer (4 active studies)
- Chronic Lymphocytic Leukemia (4 active studies)
- Stage III Laryngeal Cancer AJCC v8 (4 active studies)
Leading research sponsors in Des Moines
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- Children's Oncology Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Des Moines?
There are approximately 135 recruiting clinical trials in Des Moines, Iowa listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Des Moines pay participants?
Most recruiting trials in Des Moines compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Des Moines?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Des Moines?
The most common conditions under active study in Des Moines include Malignant Solid Neoplasm (6), Anatomic Stage II Breast Cancer AJCC v8 (5), Acute Myeloid Leukemia (4), Breast Cancer (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Des Moines?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Des Moines on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Des Moines?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Des Moines?
Recruiting research sites in Des Moines include Iowa Methodist Medical Center, UI Health Care Mission Cancer and Blood - Des Moines Clinic, UI Health Care Mission Cancer and Blood - Laurel Clinic, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Des Moines right now?
The largest active categories in Des Moines are Cancer & tumors (100), Mental health & behavior (2), Diabetes & metabolic (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.